177Lu-ITG-PSMA-1

N/A

Report date: 2025/11/20 16:00:46
NME

Base Information

Drug Name177Lu-ITG-PSMA-1
Drug Alias Name177Lu-ITG-PSMA-1177Lu-PSMA-I&TLu-177-ITG-PSMA-1
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLausanne University Hospital
China Registration ClassN/A

Develop Information

Active CompaniesLausanne University HospitalUniversity Hospital Basel
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A